- Fellowship - Dana-Farber Cancer Institute (2005-2008), Oncology
- Residency - University of California, San Francisco (2002-2005), Internal Medicine
- Medical School - Duke University School of Medicine (1993-2002)
- Graduate School - Duke University School of Medicine (1995-2001)
- Other Post Graduate Training - Duke University School of Medicine (1995-2001)
Kevin Courtney, M.D., Ph.D.
- Internal Medicine - Hematology/Oncology
- Prostate Cancer
- Genitourinary Cancer
Kevin Dale Courtney, M.D., Ph.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in prostate cancer, kidney cancer, and other genitourinary cancers and serves as co-leader of the Genitourinary Oncology Disease-Oriented Team at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center.
Dr. Courtney earned his medical degree and a doctorate in molecular cancer biology at Duke University. He completed a residency in internal medicine at the University of California, San Francisco and then received advanced training in medical oncology through a fellowship at the Dana-Farber Cancer Institute/Dana-Farber Harvard Cancer Center in Boston. He also holds a master’s degree in clinical sciences from UT Southwestern.
Certified by the American Board of Internal Medicine, he joined the UT Southwestern faculty in 2012.
Dr. Courtney’s clinical and translational research efforts are focused in genitourinary oncology, especially in prostate and kidney cancer.
He is a member of the American Society of Clinical Oncology.
- American Society of Clinical Oncology
- John W. Boddie, Ph.D. & Joan Reisch, Ph.D. Fund in Prostate Cancer Research in Honor of Dr. Kevin Courtney 2019
- Wheels for Wellness Classic Hero Award of Gratitude from the Wheels for Wellness Foundation and Moncrief Cancer Institute 2017
- UT Southwestern Medical Center and Friends of the Comprehensive Cancer Center Award in Cancer Research 2016
- UT Southwestern Golden Pager Award 2015
- Young Investigator Award 2008, American Society of Clinical Oncology
- Career Development Award 2008, Genentech, Inc. Dana-Farber/Partners Cancer Center
PI3K in Molecular Oncology: Causes of Cancer and Targets for Treatment
Courtney KD, Cantley LC (2012)
The role of ascorbate in metabolism and genotoxicity of chromium (VI). in Sarkar B, editor. Genetic Response to Metals.
Wetterhahn KE, Stearns DM, Misra M, Giangrande PH, Phieffer LS, Kennedy LJ, and Courtney KD (1995), New York, Marcel Dekker Inc.
- PI3K in Molecular Oncology: Causes of Cancer and Targets for Treatment
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD*, Ma Y*, Diaz de Leon A*, Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, Fatunde O, Arriaga Y, Frankel AE, Kalva S, Zhang S, McKenzie T, Reig Torras O, Figlin RA, Rini BI, McKay RM, Kapur P, Wang T, Pedrosa I, Brugarolas J. Clin Cancer Res. 2019
Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?
Desai NB, Courtney K, Subramaniam RM, Cadeddu JA. Eur Urol. 2019 76 740-742
MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.
Fets L, Driscoll PC, Grimm F, Jain A, Nunes PM, Gounis M, Doglioni G, Papageorgiou G, Ragan TJ, Campos S, Silva Dos Santos M, MacRae JI, O'Reilly N, Wright AJ, Benes CH, Courtney KD, House D, Anastasiou D Nature chemical biology 2018 Nov 14 11 1032-1042
Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.
Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, Margulis V, Cadeddu JA, Pedrosa I, DeBerardinis RJ, Malloy CR, Bachoo RM, Maher EA Cell metabolism 2018 Aug
Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients.
Kobayashi M, Chung JS, Beg M, Arriaga Y, Verma UN, Courtney K, Mansour JC, Haley B, Khan SA, Horiuchi Y, Ramani V, Harker D, Gopal P, Araghizadeh F, Cruz PD, Ariizumi K Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Jul
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, and Small EJ, et al., for the SPARTAN Investigators* N Engl J Med. 2018
Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB. BJU Int 2018 121 365-372
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.
Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R Oncoimmunology 2018 7 7 e1440168
Improved survival outcomes for kidney cancer patients with brain metastases.
Bowman I, Christie A, Bent A, Mickey B, Hammers H, Brugarolas J, Courtney K, Nedzi L, Hannan R, Timmerman R, Barnett S, Stojadinovic S, Whitworth T, Patel T, Le T, Arriaga Y, Wardak Z. Clinical Genitourinary Cancer. 2018
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Dec JCO2017742627
Targeting Renal Cell Carcinoma with a HIF-2 antagonist.
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J Nature 2016 Sep
Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K, Arriaga Y, Lotan Y Can J Urol 2015 22 7865-7875
A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer.
Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME Clinical genitourinary cancer 2014 Oct
Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. NEJM 2014 371 424-433
Identification of CDCP1 as a hypoxia-inducible factor 2? (HIF-2?) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS, Brown V, Signoretti S, Soltoff SP, and Cantley LC. PNAS 2013 110 3483-3488.
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD, Taplin ME Current opinion in oncology 2012 May 24 3 272-7
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer (CRPC).
Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. BJU International 2012 110 1729-35
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.
Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park HW, Cantley LC, Thomas CJ, Vander Heiden MG Nature Chemical Biology 2012 8 839-47
The PI3K pathway as drug target in human cancer
Courtney KD, Corcoran RB, Engelman JA Journal of Clinical Oncology 2010 28 1075-83
Optimizing recent advances in metastatic renal cell carcinoma
Courtney KD, Choueiri TK Current Oncology Reports 2009 11 218-226
The Abl interactor proteins localized to sites of actin polymerization at the tips of lamellipodia and filopodia
Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM Current Biology 2001 11 891-5
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, and Pendergast AM. Blood 2000 95 2913-21
Localization and phosphorylation of Abl-interactor proteins, Abi-1 and Abi-2, in the developing nervous system
Courtney KD, Grove M, Vandongen H, Vandongen A, LaMantia A-S, Pendergast AM Molecular and Cellular Neuroscience 2000 16 244-57
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway
Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM Genes and Development 1998 12 1415-24
Reduction of chromium (VI) by ascorbate leads to chromium-DNA binding and DNA strand breaks in vitro.
Stearns DM, Kennedy LJ, Courtney KD, Giangrande PH, Pheiffer LS, and Wetterhahn KE. Biochemistry 1995 34
Chromium (VI) reduction by ascorbate: role of reactive intermediates in DNA damage in vitro.
Stearns DM, Courtney KD, Giangrande PH, Phieffer LS, and Wetterhahn KE Environmental Health Perspectives 1994 102
- HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
- Clinical-Translational Research in Genitourinary Oncology
- Industry- and Cooperative Group-Sponsored Trials in Genitourinary Malignancies
- Investigator-Initiated Clinical Trials in Kidney Cancer
- Investigator-Initiated Clinical Trials in Prostate Cancer
- Novel Biomarkers and Therapeutics in Prostate and Kidney Cancer
- Metabolism in Kidney Cancer
- Prostate Cancer
- Genitourinary Cancer
- Bladder Cancer
- Kidney Cancer
- Testicular Cancer